News

The results from the multi-center, randomized Phase 2 trial showed that a single oral dose of SYM-1219 met the trial’s primary endpoint of Clinical Outcome Responder and was

Xtampza ER, Collegium’s lead product candidate, is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is being developed for the management of pain severe enough to require

In addition, Knight has entered into an exclusive distribution agreement with Ember, a cutting-edge U.S.-based biopharmaceutical company, to commercialize its promising Bone Morphogenetic Protein-7 ("BMP-7") pipeline in Canada

"Hydropothecary is now one of a few licensed producers able to make new, ingestible product lines. The products will be available for purchase following rigorous safety testing and

As part of the transaction, iCardiac has also opened a new office in Longmont, Colorado to accommodate the project management, data management, customer support, IT, technology development and

XCITE is an FDA fast tracked, pivotal Phase III trial of the company’s cancer drug Xilonix. XCITE is designed to assess improvement in overall survival of patients in

IGN002 is genetically engineered by fusing an antibody with interferon, a protein that plays a major role in regulating the immune system. The approved IND will allow Valor,

Compared to the existing standard of care chemotherapy ‘docetaxel’, the company noted that nivolumab is expected to offer significant superiority in survival rates. The approval of nivolumab, a

NICE has issued a final appraisal determination (FAD) for Lixiana to help patients with a heart flutter who have an increased risk of stroke. The draft guidance states